• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Claritev Reports Fourth Quarter and Full Year 2024 Results with Initial Guidance for Full Year 2025

    2/25/25 6:00:00 AM ET
    $MPLN
    Business Services
    Consumer Discretionary
    Get the next $MPLN alert in real time by email
    • Q4 2024 Revenues of $232.1 million, Net Loss of $138.0 million and Adjusted EBITDA of $141.6 million



    • Full Year 2024 Revenues of $930.6 million, Net Loss of $1,645.8 million and Adjusted EBITDA of $576.7 million



    • Full Year 2025 Revenues guidance of (2)% to flat as compared to FY 2024 and FY 2025 Adjusted EBITDA % guidance of 62.5% to 63.5%

    Claritev Corporation ("Claritev" or the "Company") (NYSE:MPLN), formerly known as MultiPlan, a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the fourth quarter and full year ended December 31, 2024.

    Chairman, CEO and President Travis Dalton said, "We are celebrating the rebranding launch of our new company name, which signals our turn in the transformation journey to becoming a market-leading health technology organization. I am extremely proud of our talented team of leaders and associates whose rigor and discipline have laid the foundation for our way up and forward. By focusing our purpose-built solutions across the healthcare ecosystem — including payors, employers, patients, providers and third parties — we aim to make healthcare more affordable for all."

    "We are happy with the outcome of our debt refinancing that closed last month with an aggregate 99.75% participation in the exchanges. Not only does it free up our runway and some internal resources to focus on our multi-year journey ahead, but it reinforces the level of confidence our investors have in the Vision 2030 plan that we outlined and our renewed team's ability to execute."

    Mr. Dalton concluded, "As I shared on our last earnings call, our expectation that fourth quarter results would mirror our third quarter results rang true, with a slight beat on sequential revenue and consistent adjusted EBITDA. As we start The Turn in 2025, we are working to stabilize the single-client impact and enhance our core solutions, all while staying focused on being product-led, partner-enabled and technology-driven. Our 2025 guidance reflects our view on the balancing of all these elements. I am optimistic for our future and look forward to reporting out on the progress of our journey and the great milestones along the way."

    Fourth Quarter 2024 Business and Financial Highlights

    All comparisons are to the quarter ended December 31, 2023.

    • Revenues of $232.1 million, a decrease of 4.9%, compared to revenues of $244.1 million.
    • Net loss of $138.0 million, compared to net loss of $31.4 million.
    • Adjusted EBITDA of $141.6 million, compared to Adjusted EBITDA of $156.8 million.
    • The Company ended Q4 2024 with $16.8 million of unrestricted cash and cash equivalents on the balance sheet.

    Full Year 2024 Business and Financial Highlights

    All comparisons to the year ended December 31, 2023.

    • Revenues of $930.6 million, a decrease of 3.2%, compared to revenues of $961.5 million.
    • Net loss of $1,645.8 million, compared to net loss of $91.7 million.
    • Adjusted EBITDA of $576.7 million, compared to Adjusted EBITDA of $618.0 million.
    • Net cash provided by operating activities of $107.6 million, compared to $171.7 million.
    • Free Cash Flow of $(10.5) million, compared to $62.9 million.
    • For the year ended December 31, 2024, the Company processed approximately $177.6 billion in medical charges and identified approximately $24.7 billion in potential medical cost savings compared to $168.6 billion medical charges and approximately $22.9 billion in potential medical cost savings.

    2025 Financial Guidance1

    Financial Metric

     

     

    Full Year 2025 Guidance

    Revenues

     

     

    (2)% to flat from FY 2024

    Adjusted EBITDA Margin1

     

     

    62.5% to 63.5%

    Capital expenditures

     

     

    $155 million to $165 million

    Effective tax rate

     

     

    25% to 28%

    Free Cash Flow

     

     

    $(65) to $(75) million

    1 We have not reconciled the forward-looking Adjusted EBITDA guidance included above to the most directly comparable GAAP measure because this cannot be done without unreasonable effort due to the variability and low visibility with respect to certain costs, the most significant of which are incentive compensation (including stock-based compensation), transformation-related expenses, certain fair value measurements, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.

    Conference Call Information

    The Company will host a conference call today, Tuesday, February 25, 2025, at 8:00 a.m. U.S. Eastern Time (ET) to discuss its financial results. Investors and analysts are encouraged to pre-register for the conference call by using the link below. Participants who pre-register will receive access details including a unique pin via email. Pre-registration may be completed at any time up to and following the call start time.

    To pre-register, go to: https://www.netroadshow.com/events/login?show=c3f55c26&confId=76349

    A live webcast of the conference call can be accessed through the Investor Relations section of the Company's website at investors.claritev.com/events-and-presentations. Participants should join the webcast ten minutes prior to the start of the conference call. The earnings release and supplemental slide deck will also be available on this section of the Company's website.

    For those unable to listen to the live conference call, a replay will be available approximately two hours after the call through the archived webcast on the Investor Relations section of the Company's website. For those requiring operator assistance please dial (404) 975-4839 or (833) 470-1428. The access code is 940787.

    About Claritev

    Claritev, formerly known as MultiPlan, is a healthcare technology, data and insights company focused on delivering affordability, transparency and quality to the U.S. healthcare system. Led by a team of deeply experienced associates, data scientists, and innovators, Claritev provides cutting-edge solutions and services fueled by over 40 years of claims processing data. Claritev leverages world-class technology and AI to power a robust enterprise platform that delivers meaningful insights to drive affordability and price transparency, and optimizes networks and benefits design in healthcare. By developing purpose-build solutions that support all key stakeholders - including payors, employers, patients, providers, and third parties - Claritev is dedicated to making healthcare more accessible and affordable for all.

    Claritev serves more than 700 healthcare payors, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers. For more information, visit claritev.com.

    Forward Looking Statements

    This press release includes statements that express our and our subsidiaries' opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, "forward-looking statements". These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "seeks," "projects," "forecasts," "intends," "plans," "may," "will" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this press release, including, but not limited to, statements relating to our ability to execute on our transformation plan, the anticipated benefits of our transformation plan, the anticipated benefits of our debt refinancing, our 2025 outlook and guidance, and the long-term prospects of the Company. Such forward-looking statements are based on available current market information and management's expectations, beliefs and forecasts concerning future events impacting the business. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that these forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These factors include: loss of our clients, particularly our largest clients; interruptions or security breaches of our information technology systems and other cybersecurity attacks; the ability to achieve the goals of our strategic plans and recognize the anticipated strategic, operational, growth and efficiency benefits when expected; our ability to enter new lines of business and broaden the scope of our services; the loss of key members of our management team or inability to maintain sufficient qualified personnel; our ability to continue to attract, motivate and retain a large number of skilled employees, and adapt to the effects of inflationary pressure on wages; trends in the U.S. healthcare system, including recent trends of unknown duration of reduced healthcare utilization and increased patient financial responsibility for services; effects of competition; effects of pricing pressure; our ability to identify, complete and successfully integrate acquisitions; the inability of our clients to pay for our services; changes in our industry and in industry standards and technology; our ability to protect proprietary information, processes and applications; our ability to maintain the licenses or right of use for the software we use; our inability to expand our network infrastructure; our ability to obtain additional financing; our ability to pay interest and principal on our notes and other indebtedness; lowering or withdrawal of our credit ratings; adverse outcomes related to litigation or governmental proceedings; inability to preserve or increase our existing market share or the size of our preferred provider organization networks; decreases in discounts from providers; pressure to limit access to preferred provider networks; changes in our regulatory environment, including healthcare law and regulations; the expansion of privacy and security laws; heightened enforcement activity by government agencies; the possibility that we may be adversely affected by other political, economic, business, and/or competitive factors; changes in accounting principles or the incurrence of impairment charges; other factors disclosed in our Securities and Exchange Commission ("SEC") filings; and other factors beyond our control.

    The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on our business. There can be no assurance that future developments affecting our business will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, and other documents filed or to be filed with the SEC by us. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.

    We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

    Non-GAAP Financial Measures

    In addition to the financial measures prepared in accordance with generally accepted accounting principles in the United States ("GAAP"), this press release contains certain non-GAAP financial measures, including EBITDA, Adjusted EBITDA, Free Cash Flow, Unlevered Free Cash Flow and Adjusted cash conversion ratio. A non-GAAP financial measure is generally defined as a numerical measure of a company's financial or operating performance that excludes or includes amounts so as to be different than the most directly comparable measure calculated and presented in accordance with GAAP.

    EBITDA, Adjusted EBITDA, Free Cash Flow, Unlevered Free Cash Flow and Adjusted cash conversion ratio are supplemental measures of Claritev's performance that are not required by or presented in accordance with GAAP. These measures are not measurements of our financial or operating performance under GAAP, have limitations as analytical tools and should not be considered in isolation or as an alternative to net (loss) income, cash flows or any other measures of performance prepared in accordance with GAAP.

    EBITDA represents net (loss) income before interest expense, interest income, income tax provision (benefit), depreciation, amortization of intangible assets, and non-income taxes. Adjusted EBITDA is EBITDA as further adjusted by certain items as described in the table below.

    In addition, in evaluating EBITDA and Adjusted EBITDA you should be aware that in the future, we may incur expenses similar to the adjustments in the presentation of EBITDA and Adjusted EBITDA. The presentation of EBITDA and Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. The calculations of EBITDA and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. Based on our industry and debt financing experience, we believe that EBITDA and Adjusted EBITDA are customarily used by investors, analysts and other interested parties to provide useful information regarding a company's ability to service and/or incur indebtedness.

    We also believe that Adjusted EBITDA is useful to investors and analysts in assessing our operating performance during the periods these charges were incurred on a consistent basis with the periods during which these charges were not incurred. Both EBITDA and Adjusted EBITDA have limitations as analytical tools, and you should not consider either in isolation, or as a substitute for analysis of our results as reported under GAAP. Some of the limitations are:

    • EBITDA and Adjusted EBITDA do not reflect changes in, or cash requirements for, our working capital needs;
    • EBITDA and Adjusted EBITDA do not reflect interest expense, or the cash requirements necessary to service interest or principal payments on our debt;
    • EBITDA and Adjusted EBITDA do not reflect our tax expense or the cash requirements to pay our taxes; and
    • Although depreciation and amortization are non-cash charges, the tangible assets being depreciated will often have to be replaced in the future, and EBITDA and Adjusted EBITDA do not reflect any cash requirements for such replacements.

    Claritev's presentation of Adjusted EBITDA should not be construed as an inference that our future results and financial position will be unaffected by unusual items.

    Free Cash Flow is defined as net cash provided by operating activities less capital expenditures, all as disclosed in the Statements of Cash Flows. Unlevered Free Cash Flow is defined as net cash provided by operating activities less capital expenditures, plus cash interest paid, all as disclosed in the Statements of Cash Flows. Free Cash Flow and Unlevered Free Cash Flow are measures of our operational performance used by management to evaluate our business after purchases of property and equipment and, in the case of Unlevered Free Cash Flow, prior to the impact of our capital structure. Free Cash Flow and Unlevered Free Cash Flow should be considered in addition to, rather than as a substitute for, consolidated net income as a measure of our performance and net cash provided by operating activities as a measure of our liquidity. Additionally, Claritev's definitions of Free Cash Flow and Unlevered Free Cash Flow are limited, in that they do not represent residual cash flows available for discretionary expenditures, due to the fact that the measures do not deduct the payments required for debt service, in the case of Unlevered Free Cash Flow, and other contractual obligations or payments made for business acquisitions.

    Adjusted cash conversion ratio is defined as Unlevered Free Cash Flow divided by Adjusted EBITDA. Claritev believes that the presentation of the Adjusted cash conversion ratio provides useful information to investors because it is an financial performance measure that shows how much of its Adjusted EBITDA Claritev converts into Unlevered Free Cash Flow.

     

    CLARITEV CORPORATION

    Consolidated Balance Sheets

    (in thousands, except share and per share data)

     
     

    ​

    December 31,

    ​

     

    2024

     

     

     

    2023

     

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    16,848

     

     

    $

    71,547

     

    Restricted cash

     

    12,824

     

     

     

    9,947

     

    Trade accounts receivable, net

     

    89,758

     

     

     

    76,558

     

    Unbilled Independent Dispute Resolution fees, net

     

    21,850

     

     

     

    8,197

     

    Prepaid expenses

     

    20,493

     

     

     

    23,432

     

    Prepaid taxes

     

    6,747

     

     

     

    1,364

     

    Other current assets, net

     

    6,995

     

     

     

    2,548

     

    Total current assets

     

    175,515

     

     

     

    193,593

     

    Property and equipment, net

     

    292,649

     

     

     

    267,429

     

    Operating lease right-of-use assets

     

    16,097

     

     

     

    19,680

     

    Goodwill

     

    2,403,140

     

     

     

    3,829,002

     

    Other intangibles, net

     

    2,226,323

     

     

     

    2,633,207

     

    Other assets, net

     

    37,103

     

     

     

    21,776

     

    Total assets

    $

    5,150,827

     

     

    $

    6,964,687

     

    Liabilities and Shareholders' Equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    86,327

     

     

    $

    19,590

     

    Accrued interest

     

    55,532

     

     

     

    56,827

     

    Operating lease obligation, short-term

     

    4,385

     

     

     

    4,792

     

    Current portion of long-term debt

     

    13,250

     

     

     

    13,250

     

    Accrued compensation

     

    33,690

     

     

     

    44,720

     

    Accrued legal contingencies

     

    1,623

     

     

     

    12,123

     

    Other accrued expenses

     

    18,983

     

     

     

    15,437

     

    Total current liabilities

     

    213,790

     

     

     

    166,739

     

    Long-term debt

     

    4,509,725

     

     

     

    4,532,733

     

    Operating lease obligation, long-term

     

    13,857

     

     

     

    17,124

     

    Private Placement Warrants and Unvested Founder Shares

     

    —

     

     

     

    477

     

    Deferred income taxes

     

    325,834

     

     

     

    521,707

     

    Other liabilities

     

    3,599

     

     

     

    16,783

     

    Total liabilities

     

    5,066,805

     

     

     

    5,255,563

     

    Shareholders' equity:

     

     

     

    Shareholder interests

     

     

     

    Preferred stock, $0.0001 par value — 10,000,000 shares authorized; no shares issued

     

    —

     

     

     

    —

     

    Common stock, $0.0001 par value — 1,500,000,000 shares authorized; 16,930,827 and 16,695,207 issued; 16,187,968 and 16,207,984 shares outstanding

     

    2

     

     

     

    2

     

    Additional paid-in capital

     

    2,372,954

     

     

     

    2,348,570

     

    Accumulated other comprehensive loss

     

    (5,063

    )

     

     

    (11,778

    )

    Retained deficit

     

    (2,145,138

    )

     

     

    (499,307

    )

    Treasury stock — 742,859 and 487,223 shares

     

    (138,733

    )

     

     

    (128,363

    )

    Total shareholders' equity

     

    84,022

     

     

     

    1,709,124

     

    Total liabilities and shareholders' equity

    $

    5,150,827

     

     

    $

    6,964,687

     

     

    CLARITEV CORPORATION

    Consolidated Statements of Loss and Comprehensive Loss

    (in thousands, except share and per share data)

     
     

     

     

    Years Ended December 31,

     

     

     

    2024

     

     

     

    2023

     

    Revenues

     

    $

    930,624

     

     

    $

    961,524

     

    Costs of services (exclusive of depreciation and amortization of intangible assets shown below)

     

     

    239,404

     

     

     

    235,468

     

    General and administrative expenses

     

     

    160,215

     

     

     

    144,057

     

    Depreciation

     

     

    88,190

     

     

     

    77,323

     

    Amortization of intangible assets

     

     

    343,883

     

     

     

    342,694

     

    Loss on impairment of goodwill and intangible assets

     

     

    1,488,863

     

     

     

    —

     

    Total expenses

     

     

    2,320,555

     

     

     

    799,542

     

    Operating (loss) income

     

     

    (1,389,931

    )

     

     

    161,982

     

    Interest expense

     

     

    326,371

     

     

     

    333,208

     

    Interest income

     

     

    (3,130

    )

     

     

    (8,233

    )

    Transaction Costs - Refinancing Transaction

     

     

    63,930

     

     

     

    —

     

    Gain on extinguishment of debt

     

     

    (5,913

    )

     

     

    (53,968

    )

    Gain on change in fair value of Private Placement Warrants and Unvested Founder Shares

     

     

    (477

    )

     

     

    (1,965

    )

    Net loss before taxes

     

     

    (1,770,712

    )

     

     

    (107,060

    )

    Benefit for income taxes

     

     

    (124,881

    )

     

     

    (15,363

    )

    Net loss

     

    $

    (1,645,831

    )

     

    $

    (91,697

    )

     

     

     

     

     

    Weighted average shares outstanding – Basic and Diluted

     

     

    16,147,506

     

     

     

    16,128,366

     

     

     

     

     

     

    Net loss per share – Basic and Diluted

     

    $

    (101.92

    )

     

    $

    (5.69

    )

     

     

     

     

     

    Net loss

     

    $

    (1,645,831

    )

     

    $

    (91,697

    )

    Other comprehensive income:

     

     

     

     

    Unrealized gain (loss) on interest rate swap, net of tax

     

     

    6,715

     

     

     

    (11,778

    )

    Comprehensive loss

     

    $

    (1,639,116

    )

     

    $

    (103,475

    )

     

    CLARITEV CORPORATION

    Consolidated Statements of Cash Flows

    (in thousands)

     
     

     

    Years Ended December 31,

     

     

    2024

     

     

     

    2023

     

    Operating activities:

     

     

     

    Net loss

    $

    (1,645,831

    )

     

    $

    (91,697

    )

    Adjustments to reconcile net (loss) income to net cash provided by operating activities:

     

     

     

    Depreciation

     

    88,190

     

     

     

    77,323

     

    Amortization of intangible assets

     

    343,883

     

     

     

    342,694

     

    Amortization of the right-of-use asset

     

    4,364

     

     

     

    5,769

     

    Loss on impairment of goodwill and intangible assets

     

    1,488,863

     

     

     

    —

     

    Stock-based compensation

     

    26,645

     

     

     

    18,018

     

    Deferred income taxes

     

    (198,008

    )

     

     

    (114,060

    )

    Amortization of debt issuance costs and discounts

     

    10,974

     

     

     

    10,663

     

    Gain on extinguishment of debt

     

    (5,913

    )

     

     

    (53,968

    )

    Loss on disposal of property and equipment

     

    8,595

     

     

     

    851

     

    Change in fair value of Private Placement Warrants and Unvested Founder Shares

     

    (477

    )

     

     

    (1,965

    )

    Changes in assets and liabilities, net of assets acquired and liabilities assumed from acquisitions:

     

     

     

    Accounts receivable, net

     

    (13,200

    )

     

     

    4,402

     

    Prepaid expenses and other assets

     

    (31,761

    )

     

     

    (6,615

    )

    Prepaid taxes

     

    (5,383

    )

     

     

    (13

    )

    Operating lease obligation

     

    (5,541

    )

     

     

    (6,601

    )

    Accounts payable and accrued expenses and other

     

    42,216

     

     

     

    (13,081

    )

    Net cash provided by operating activities

     

    107,616

     

     

     

    171,720

     

    Investing activities:

     

     

     

    Purchases of property and equipment

     

    (118,123

    )

     

     

    (108,852

    )

    BST Acquisition, net of cash acquired

     

    —

     

     

     

    (140,940

    )

    Net cash used in investing activities

     

    (118,123

    )

     

     

    (249,792

    )

    Financing activities:

     

     

     

    Repayments of Term Loan B

     

    (13,250

    )

     

     

    (13,250

    )

    Repurchase of 5.750% Notes

     

    —

     

     

     

    (134,975

    )

    Repurchase of Senior Convertible PIK Notes

     

    (14,886

    )

     

     

    (17,563

    )

    Taxes paid on settlement of vested share awards

     

    (3,356

    )

     

     

    (465

    )

     

    CLARITEV CORPORATION

    Consolidated Statements of Cash Flows (continued)

    (in thousands)

     
     

     

    Years Ended December 31,

     

     

    2024

     

     

     

    2023

     

    Purchase of treasury stock

     

    (10,370

    )

     

     

    (15,218

    )

    Payment of debt issuance costs

     

    (615

    )

     

     

    —

     

    Borrowings on finance leases, net

     

    67

     

     

     

    (30

    )

    Proceeds from issuance of common stock under Employee Stock Purchase Plan

     

    1,095

     

     

     

    508

     

    Net cash used in financing activities

     

    (41,315

    )

     

     

    (180,993

    )

    Net increase (decrease) in cash, cash equivalents and restricted cash

     

    (51,822

    )

     

     

    (259,065

    )

    Cash, cash equivalents and restricted cash at beginning of period

     

    81,494

     

     

     

    340,559

     

    Cash, cash equivalents and restricted cash at end of period

    $

    29,672

     

     

    $

    81,494

     

     

     

     

     

    Cash and cash equivalents

    $

    16,848

     

     

    $

    71,547

     

    Restricted cash

     

    12,824

     

     

     

    9,947

     

    Cash, cash equivalents and restricted cash at end of period

    $

    29,672

     

     

    $

    81,494

     

     

     

     

     

    Noncash investing and financing activities:

     

     

     

    Purchases of property and equipment not yet paid

    $

    12,530

     

     

    $

    8,649

     

    Operating lease right-of-use assets obtained in exchange for operating lease liabilities

    $

    5,015

     

     

    $

    1,304

     

    Debt issuance costs not yet paid

     

    4,267

     

     

     

    —

     

    Supplemental disclosure of cash flow information:

     

     

     

    Cash paid during the period for:

     

     

     

    Interest

    $

    (315,245

    )

     

    $

    (323,396

    )

    Income taxes, net of refunds

    $

    (80,089

    )

     

    $

    (100,083

    )

     

    CLARITEV CORPORATION

    Calculation of EBITDA and Adjusted EBITDA

    (in thousands)

     
     

     

     

    Year Ended December 31,

     

     

     

    2024

     

     

     

    2023

     

     

     

     

     

     

    Net loss

     

    $

    (1,645,831

    )

     

    $

    (91,697

    )

    Adjustments:

     

     

     

     

    Interest expense

     

     

    326,371

     

     

     

    333,208

     

    Interest income

     

     

    (3,130

    )

     

     

    (8,233

    )

    Income tax benefit

     

     

    (124,881

    )

     

     

    (15,363

    )

    Depreciation

     

     

    88,190

     

     

     

    77,323

     

    Amortization of intangible assets

     

     

    343,883

     

     

     

    342,694

     

    Non-income taxes

     

     

    2,338

     

     

     

    2,283

     

    EBITDA

     

    $

    (1,013,060

    )

     

    $

    640,215

     

    Adjustments:

     

     

     

     

    Other expenses, net (1)

     

     

    5,402

     

     

     

    3,472

     

    Loss on disposal of assets

     

     

    8,595

     

     

     

    851

     

    Integration expenses

     

     

    2,683

     

     

     

    3,358

     

    Change in fair value of Private Placement Warrants and Unvested Founder Shares

     

     

    (477

    )

     

     

    (1,965

    )

    Transaction-related expenses

     

     

    —

     

     

     

    8,064

     

    Transaction Costs - Refinancing Transaction

     

     

    63,930

     

     

     

    —

     

    Gain on extinguishment of debt

     

     

    (5,913

    )

     

     

    (53,968

    )

    Loss on impairment of goodwill and intangible assets

     

     

    1,488,863

     

     

     

    —

     

    Stock-based compensation

     

     

    26,645

     

     

     

    18,018

     

    Adjusted EBITDA

     

    $

    576,668

     

     

    $

    618,045

     

    (1) "Other expenses, net" represents miscellaneous non-recurring expenses, impairment of other assets, gain or loss on disposal of leases, tax penalties, non-integration related severance costs, implementation costs for cloud computing arrangements, and transformation costs including internal labor.

     

    CLARITEV CORPORATION

    Calculation of Free Cash Flow, Unlevered Free Cash Flow and Adjusted Cash Conversion Ratio

    (in thousands)

     
     

     

     

    Year Ended December 31,

     

     

     

    2024

     

     

     

    2023

     

     

     

     

     

     

    Net cash provided by operating activities

     

    $

    107,616

     

     

    $

    171,720

     

    Purchases of property and equipment

     

     

    (118,123

    )

     

     

    (108,852

    )

    Free Cash Flow

     

     

    (10,507

    )

     

     

    62,868

     

    Interest paid

     

     

    315,245

     

     

     

    323,396

     

    Unlevered Free Cash Flow

     

    $

    304,738

     

     

    $

    386,264

     

     

     

     

     

     

    Adjusted EBITDA

     

    $

    576,668

     

     

    $

    618,045

     

    Adjusted Cash Conversion Ratio

     

     

    53

    %

     

     

    62

    %

     

     

     

     

     

    Net cash used in investing activities

     

    $

    (118,123

    )

     

    $

    (249,792

    )

    Net cash used in financing activities

     

    $

    (41,315

    )

     

    $

    (180,993

    )

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250225859765/en/

    Investor Relations Contact

    Jason Wong

    SVP, Treasury & Investor Relations

    Claritev

    866-909-7427

    [email protected]



    Shawna Gasik

    AVP, Investor Relations

    Claritev

    866-909-7427

    [email protected]

    Get the next $MPLN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MPLN

    DatePrice TargetRatingAnalyst
    6/26/2024$2.00Neutral
    Piper Sandler
    12/13/2022$3.00 → $2.00Buy → Neutral
    Citigroup
    7/12/2022$6.50Neutral
    Goldman
    12/20/2021$9.00 → $7.00Buy
    Citigroup
    11/11/2021$7.00 → $6.00Equal-Weight
    Barclays
    10/4/2021$9.00Buy
    Citigroup
    8/20/2021$9.00Buy
    Tigress Financial
    More analyst ratings

    $MPLN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ClearNote Health's Avantect® Pancreatic Cancer Test Now Available to Health Plan Members Accessing Claritev's National PPO Networks

      Latest agreement expands access to the PHCS and MultiPlan Networks ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced an agreement with Claritev, Inc. ("Claritev") (NYSE:CTEV), previously MultiPlan, Inc. (NYSE:MPLN), a technology and data insights company focused on making healthcare more affordable, transparent, and fair for all. As part of the agreement, ClearNote Health's Avantect® Pancreatic Cancer Test will now be available to health plan members accessing Claritev's national PHCS and MultiPlan Networks. While early detection has vastly improved survival rates for many types of cancer, pancreatic cancer is often diagnos

      3/12/25 8:03:00 AM ET
      $CTEV
      $MPLN
      Business Services
      Consumer Discretionary
    • Claritev Reports Fourth Quarter and Full Year 2024 Results with Initial Guidance for Full Year 2025

      Q4 2024 Revenues of $232.1 million, Net Loss of $138.0 million and Adjusted EBITDA of $141.6 million Full Year 2024 Revenues of $930.6 million, Net Loss of $1,645.8 million and Adjusted EBITDA of $576.7 million Full Year 2025 Revenues guidance of (2)% to flat as compared to FY 2024 and FY 2025 Adjusted EBITDA % guidance of 62.5% to 63.5% Claritev Corporation ("Claritev" or the "Company") (NYSE:MPLN), formerly known as MultiPlan, a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the fourth quarter and full year ended December 31, 2024. Chairman, CEO and President Travis Dalt

      2/25/25 6:00:00 AM ET
      $MPLN
      Business Services
      Consumer Discretionary
    • Claritev Provides Oracle Cloud HCM Customers with Actionable Insights for Healthcare Cost Optimization and Plan Design

      Claritev's Award-Winning Analytics Solution, BenInsights®, is Powered by Oracle Cloud and Now Available in the Oracle Cloud Marketplace Claritev Corporation ("Claritev" or the "Company") (NYSE:MPLN), formerly known as MultiPlan, a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, and an Oracle partner, announced today its analytics solution, BenInsights®, has achieved Integrated with Oracle Cloud Expertise and is now available in the Oracle Cloud Marketplace, offering added value to Oracle Cloud customers. The BenInsights platform enables visibility into benefit plan performance and compliance responsibilities for employers of

      2/21/25 8:00:00 AM ET
      $MPLN
      Business Services
      Consumer Discretionary

    $MPLN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Chief Information Officer Kim Michael bought $249,588 worth of shares (40,000 units at $6.24), increasing direct ownership by 3% to 1,312,772 units (SEC Form 4)

      4 - MultiPlan Corp (0001793229) (Issuer)

      11/19/24 4:35:27 PM ET
      $MPLN
      Business Services
      Consumer Discretionary
    • SVP, Corp. Affairs/Strategy Mintz William B. bought $104,359 worth of shares (278,165 units at $0.38), increasing direct ownership by 14% to 2,206,736 units (SEC Form 4)

      4 - MultiPlan Corp (0001793229) (Issuer)

      8/8/24 4:30:55 PM ET
      $MPLN
      Business Services
      Consumer Discretionary
    • Pres., Chief Executive Officer Dalton Travis bought $185,000 worth of shares (500,000 units at $0.37), increasing direct ownership by 11% to 5,004,504 units (SEC Form 4)

      4 - MultiPlan Corp (0001793229) (Issuer)

      8/7/24 6:05:14 PM ET
      $MPLN
      Business Services
      Consumer Discretionary

    $MPLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by SVP, Chief Information Officer Kim Michael

      4/A - MultiPlan Corp (0001793229) (Issuer)

      12/13/24 4:28:52 PM ET
      $MPLN
      Business Services
      Consumer Discretionary
    • SVP, Chief Information Officer Kim Michael bought $249,588 worth of shares (40,000 units at $6.24), increasing direct ownership by 3% to 1,312,772 units (SEC Form 4)

      4 - MultiPlan Corp (0001793229) (Issuer)

      11/19/24 4:35:27 PM ET
      $MPLN
      Business Services
      Consumer Discretionary
    • SVP, Chief Growth Officer Misencik Tiffani was granted 95,328 shares (SEC Form 4)

      4 - MultiPlan Corp (0001793229) (Issuer)

      10/16/24 5:01:01 PM ET
      $MPLN
      Business Services
      Consumer Discretionary

    $MPLN
    SEC Filings

    See more
    • SEC Form 10-K filed by MultiPlan Corporation

      10-K - Claritev Corp (0001793229) (Filer)

      2/26/25 7:50:06 AM ET
      $MPLN
      Business Services
      Consumer Discretionary
    • MultiPlan Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Claritev Corp (0001793229) (Filer)

      2/25/25 6:21:17 AM ET
      $MPLN
      Business Services
      Consumer Discretionary
    • MultiPlan Corporation filed SEC Form 8-K: Other Events

      8-K - Claritev Corp (0001793229) (Filer)

      2/24/25 8:02:11 AM ET
      $MPLN
      Business Services
      Consumer Discretionary

    $MPLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on MultiPlan with a new price target

      Piper Sandler initiated coverage of MultiPlan with a rating of Neutral and set a new price target of $2.00

      6/26/24 7:57:01 AM ET
      $MPLN
      Business Services
      Consumer Discretionary
    • MultiPlan downgraded by Citigroup with a new price target

      Citigroup downgraded MultiPlan from Buy to Neutral and set a new price target of $2.00 from $3.00 previously

      12/13/22 9:12:38 AM ET
      $MPLN
      Business Services
      Consumer Discretionary
    • Goldman initiated coverage on MultiPlan with a new price target

      Goldman initiated coverage of MultiPlan with a rating of Neutral and set a new price target of $6.50

      7/12/22 7:32:35 AM ET
      $MPLN
      Business Services
      Consumer Discretionary

    $MPLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by MultiPlan Corporation

      SC 13G/A - MultiPlan Corp (0001793229) (Subject)

      11/12/24 4:00:27 PM ET
      $MPLN
      Business Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by MultiPlan Corporation

      SC 13G/A - MultiPlan Corp (0001793229) (Subject)

      11/4/24 3:13:44 PM ET
      $MPLN
      Business Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by MultiPlan Corporation

      SC 13G/A - MultiPlan Corp (0001793229) (Subject)

      11/4/24 1:43:06 PM ET
      $MPLN
      Business Services
      Consumer Discretionary

    $MPLN
    Financials

    Live finance-specific insights

    See more
    • Claritev Reports Fourth Quarter and Full Year 2024 Results with Initial Guidance for Full Year 2025

      Q4 2024 Revenues of $232.1 million, Net Loss of $138.0 million and Adjusted EBITDA of $141.6 million Full Year 2024 Revenues of $930.6 million, Net Loss of $1,645.8 million and Adjusted EBITDA of $576.7 million Full Year 2025 Revenues guidance of (2)% to flat as compared to FY 2024 and FY 2025 Adjusted EBITDA % guidance of 62.5% to 63.5% Claritev Corporation ("Claritev" or the "Company") (NYSE:MPLN), formerly known as MultiPlan, a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the fourth quarter and full year ended December 31, 2024. Chairman, CEO and President Travis Dalt

      2/25/25 6:00:00 AM ET
      $MPLN
      Business Services
      Consumer Discretionary
    • MultiPlan Corporation Announces Fourth Quarter and Full Year 2024 Earnings Conference Call

      MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading provider of technology and data solutions that improve affordability, quality and transparency in healthcare, announced today that it will release its fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, and hold its conference call that morning at 8:00 am Eastern Time. To join the conference call, please pre-register using the link below. Participants who pre-register will receive a calendar invitation with call access details including a unique pin. Pre-registration may be completed at any time up to and following the call start time. To pre-register, go to: https://www.netroadsho

      1/28/25 8:30:00 AM ET
      $MPLN
      Business Services
      Consumer Discretionary
    • MultiPlan Reports Third Quarter 2024 Results and Updates 2024 Guidance

      – Q3 2024 Revenues of $230.5 million, Net Loss of $391.5 million (including a $361.6 million impairment of goodwill and indefinite-lived intangibles), and Adjusted EBITDA of $141.6 million – Identified potential medical cost savings of approximately $6.4 billion in Q3 2024, up 10% from Q3 2023 and up 3% from Q2 2024 MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading provider of data-driven cost management solutions that deliver transparency and promote fairness, quality and affordability to the U.S. healthcare industry, today reported financial results for the third quarter ended September 30, 2024 and updated its full-year 2024 guidance. CEO Travis Dalton said,

      11/5/24 6:00:00 AM ET
      $MPLN
      Business Services
      Consumer Discretionary

    $MPLN
    Leadership Updates

    Live Leadership Updates

    See more
    • MultiPlan Appoints Tiffani Misencik to Drive Strategic Growth

      Tiffani Misencik Named Chief Growth Officer in New Executive Leadership Role MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading provider of data-driven cost management solutions that deliver transparency and promote fairness, quality and affordability to the U.S. healthcare industry, today announced a new addition to its executive leadership team to support the next phase of the Company's strategic growth. Tiffani Misencik has been appointed Chief Growth Officer. In this newly created role, Misencik will oversee MultiPlan's sales and revenue growth strategy across all market segments. She will lead the company's efforts in client acquisition, client management, an

      10/22/24 2:00:00 PM ET
      $MPLN
      Business Services
      Consumer Discretionary
    • MultiPlan Makes Fortune's Best Workplaces in Health Care List for Second Year in a Row

      MultiPlan Corporation (NYSE:MPLN) ("MultiPlan" or the "Company"), a leading provider of technology and data-enabled cost management, payment, and revenue integrity solutions to the U.S. health care industry, is honored to announce it has been named in the 2024 Fortune Best Workplaces in Health Care™ List. based on its 2023-2024 Great Place to Work® Certification™ results. This is the second time MultiPlan has been named in the Best Workplaces in Health Care list. Earning a spot means that MultiPlan is one of the best companies to work for in the country. The Best Workplaces in Health Care list is based on analysis of survey responses from over 185,000 employees from Great Place To Work Cer

      9/12/24 8:30:00 AM ET
      $MPLN
      Business Services
      Consumer Discretionary
    • MultiPlan Announces CFO Transition

      MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading value-added provider of data analytics and technology-enabled end-to-end cost management, as well as payment and revenue integrity solutions to the U.S. healthcare industry, announced today its CFO transition plan and named Doug Garis as EVP and CFO, effective August 5, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240731993142/en/Doug Garis named EVP and CFO of MultiPlan (Photo: Business Wire) Jim Head, who has served as EVP and CFO of MultiPlan since November 2021, will transition to a Strategic Advisor role to the Company through the end of the

      8/1/24 6:00:00 AM ET
      $DOOR
      $MPLN
      $ORCL
      $CERN
      Forest Products
      Basic Materials
      Business Services
      Consumer Discretionary